Request Call Back

Contact Us

NovoSeven
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date you started taking this drug:

Date you stopped taking this drug:

Did the injured person experience any of the following:



Please describe side effects:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

NovoSeven

NovoSeven Side Effects Lawsuits | Side Effects: Heart Attacks, Strokes, Blood Clots
CLICK HERE TO DOWNLOAD OUR NOVOSEVEN INFORMATION PACKAGE

NovoSeven Side Effects Could Lead To Stroke Lawsuits

NovonSeven | Lawsuits, Lawyers | Side Effects: Heart Attacks, Strokes, Blood Clots

NovoSeven (Generic: Factor vIIa, Recombinant), a hemophilia drug manufactured by Novo Nordisk, has been linked to strokes, heart attacks, deaths and other complications in some patients. NovoSeven was approved as a clotting drug in 1999 to stop bleeding in hemophiliacs. Use of NovoSeven to treat cerebral hemorrhages, a sometimes lethal type of stroke where there is bleeding in the brain, has been off-label. Novo Nordisk has admitted that off-label use of NovoSeven causes complications in certain groups of patients including the elderly, those with underlying heart disease, and those with acute injuries.

NovoSeven Injury Data

In October 2005, the label of NovoSeven was changed to include information on side effects in patients without hemophilia. Recent adverse effect data published in the Journal of the American Medical Association included 431 reports of adverse events ranging from minor to death over the drug's first five years. According to the research, the drug's clotting action may have led to strokes, heart attacks and other serious complications in 185 cases. The study found that most of the reported events were with off-label uses and happened within 24 hours of the last dose of NovoSeven.

Increased Off-Label Use

NovoSeven costs $7,500 per dose. Since its approval, it has been used for other uses than hemophilia such as stemming bleeding from surgery, injuries or strokes. Off-label usage of the drug has resulted in an increase in users from 349 patients in 2000 to over 4,500 in 2004. NovoSeven Risks Were Previously Known: A study published in 2005 in the New England Journal of Medicine and funded by Novo Nordisk showed that NovoSeven can help patients with bleeding strokes. That study also found that there were complications including heart attacks and strokes caused by blood clots.

NovoSeven Victims Legal Rights

If you or a loved one suffered side effects due to NovoSeven, please fill out the form at the right for a free case evaluation by a qualified defective drugs attorney or call us anytime at 1-800-YOURLAWYER (1-800-968-7529).



 

NovoSevenRSS Feed

Off-Label Use of Blood Clotting Drug, NovoSeven, Linked to Deaths and Strokes - FDA

Jan 19, 2006 | www.newsinferno.com
According to the FDA, a blood clotting drug for hemophiliacs has been linked to heart attacks, strokes, deaths, and other health complications in patients given the medicine for other types of out-of-control bleeding, such as cerebral hemorrhages.NovoSeven, manufactured by Danish pharmaceutical company Novo Nordisk (Novo), was released on the market in 1999 after gaining fast-track approval from the FDA.Originally designed for and approved by the FDA for stopping bleeding in hemophiliacs, the...

Safety Questions Arise on Blood Clot Drug

Jan 17, 2006 | AP
 A hemophilia drug has been linked to deaths, strokes, heart attacks and other complications in patients given the medicine for other types of out-of-control bleeding, such as cerebral hemorrhages, according to FDA researchers.The medicine, NovoSeven, is a clotting drug that was introduced in 1999 after being approved by the Food and Drug Administration to stop bleeding in hemophiliacs. But it has also shown promise in treating cerebral hemorrhages, a potentially lethal type of stroke...

More NovoSeven News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo